ATE208633T1 - Immunokonjugate - Google Patents
ImmunokonjugateInfo
- Publication number
- ATE208633T1 ATE208633T1 AT95113956T AT95113956T ATE208633T1 AT E208633 T1 ATE208633 T1 AT E208633T1 AT 95113956 T AT95113956 T AT 95113956T AT 95113956 T AT95113956 T AT 95113956T AT E208633 T1 ATE208633 T1 AT E208633T1
- Authority
- AT
- Austria
- Prior art keywords
- immunoconjugates
- family
- interleukin
- fragment
- monoclonal antibody
- Prior art date
Links
- 229940127121 immunoconjugate Drugs 0.000 title abstract 3
- 102000004890 Interleukin-8 Human genes 0.000 abstract 2
- 108090001007 Interleukin-8 Proteins 0.000 abstract 2
- XKTZWUACRZHVAN-VADRZIEHSA-N interleukin-8 Chemical compound C([C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@@H](NC(C)=O)CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CCSC)C(=O)N1[C@H](CCC1)C(=O)N1[C@H](CCC1)C(=O)N[C@@H](C)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC=1C=CC(O)=CC=1)C(=O)N[C@H](CO)C(=O)N1[C@H](CCC1)C(N)=O)C1=CC=CC=C1 XKTZWUACRZHVAN-VADRZIEHSA-N 0.000 abstract 2
- 229940096397 interleukin-8 Drugs 0.000 abstract 2
- 102000019034 Chemokines Human genes 0.000 abstract 1
- 108010012236 Chemokines Proteins 0.000 abstract 1
- 102000001301 EGF receptor Human genes 0.000 abstract 1
- 108060006698 EGF receptor Proteins 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 230000003399 chemotactic effect Effects 0.000 abstract 1
- 231100000433 cytotoxic Toxicity 0.000 abstract 1
- 230000001472 cytotoxic effect Effects 0.000 abstract 1
- 239000012634 fragment Substances 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/582—Recycling of unreacted starting or intermediate materials
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Cell Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP94114572 | 1994-09-16 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE208633T1 true ATE208633T1 (de) | 2001-11-15 |
Family
ID=8216289
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT95113956T ATE208633T1 (de) | 1994-09-16 | 1995-09-06 | Immunokonjugate |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US5824782A (de) |
| EP (1) | EP0706799B1 (de) |
| JP (2) | JP3865802B2 (de) |
| KR (1) | KR100386171B1 (de) |
| CN (1) | CN1123185A (de) |
| AT (1) | ATE208633T1 (de) |
| AU (1) | AU702184B2 (de) |
| CA (1) | CA2158322C (de) |
| CZ (1) | CZ289641B6 (de) |
| DE (1) | DE69523857T2 (de) |
| DK (1) | DK0706799T3 (de) |
| ES (1) | ES2167391T3 (de) |
| HU (1) | HU221989B1 (de) |
| NO (1) | NO315976B1 (de) |
| PL (1) | PL182636B1 (de) |
| PT (1) | PT706799E (de) |
| RU (1) | RU2157701C2 (de) |
| SK (1) | SK282263B6 (de) |
| UA (1) | UA40611C2 (de) |
| ZA (1) | ZA957808B (de) |
Families Citing this family (90)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7276488B2 (en) * | 1997-06-04 | 2007-10-02 | Oxford Biomedica (Uk) Limited | Vector system |
| WO2001036486A2 (en) * | 1999-11-18 | 2001-05-25 | Oxford Biomedica (Uk) Limited | Scfv antibodies against disease associated molecules |
| CA2292760A1 (en) * | 1997-06-04 | 1998-12-10 | Oxford Biomedica (Uk) Limited | Vector |
| US7635687B2 (en) * | 1997-06-04 | 2009-12-22 | Oxford Biomedica (Uk) Limited | Vector system |
| ATE267215T1 (de) | 1997-12-08 | 2004-06-15 | Lexigen Pharm Corp | Heterodimäre fusionsproteine zur verwendung für gezielte immuntherapie und allgemeine immunerregung |
| WO1999046392A1 (en) * | 1998-03-12 | 1999-09-16 | The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Methods and compositions of chemokine-tumor antigen fusion proteins as cancer vaccines |
| AU746043B2 (en) * | 1998-03-31 | 2002-04-11 | Tanabe Seiyaku Co., Ltd. | Preventives/remedies for urinary disorder |
| CA2328076C (en) * | 1998-04-15 | 2009-10-06 | Lexigen Pharmaceuticals Corporation | Enhancement of antibody-cytokine fusion protein mediated immune responses by co-administration with angiogenesis inhibitor |
| EP1071469A2 (de) * | 1998-04-17 | 2001-01-31 | Lexigen Pharmaceuticals Corp. | Steigerung der antikörper-zytokin-fusionsproteinmediierten immunantwort durch mitverabreichung mit einem prostaglandininhibitor |
| US6869606B1 (en) | 1999-02-22 | 2005-03-22 | Millennium Pharmaceuticals, Inc. | Biotinylated-chemokine antibody complexes |
| AU5617900A (en) * | 1999-06-17 | 2001-01-09 | Robert C. Gallo | Chimeric chemokine-antigen polypeptides and uses therefor |
| GB9915074D0 (en) * | 1999-06-28 | 1999-08-25 | Cortecs Plc | Ligand-binding composition |
| SK782002A3 (en) | 1999-07-21 | 2003-08-05 | Lexigen Pharm Corp | FC fusion proteins for enhancing the immunogenicity of protein and peptide antigens |
| US7067110B1 (en) | 1999-07-21 | 2006-06-27 | Emd Lexigen Research Center Corp. | Fc fusion proteins for enhancing the immunogenicity of protein and peptide antigens |
| ATE316982T1 (de) | 1999-08-09 | 2006-02-15 | Lexigen Pharm Corp | Mehrere zytokin-antikörper komplexen |
| JP2003514552A (ja) | 1999-11-12 | 2003-04-22 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフトング | 改善された性質を有するエリトロポエチンの形態 |
| US6319675B1 (en) | 1999-11-24 | 2001-11-20 | Millennium Pharmaceuticals, Inc. | Methods for detecting and/or identifying agents which bind and/or modulate function of “bonzo” chemokine receptor |
| US7208152B2 (en) * | 1999-11-24 | 2007-04-24 | Millennium Pharmaceuticals, Inc. | Antibodies for “Bonzo” chemokine receptor and therapeutic uses thereof |
| AU4314801A (en) | 2000-02-11 | 2001-08-20 | Lexigen Pharm Corp | Enhancing the circulating half-life of antibody-based fusion proteins |
| DE10019157A1 (de) * | 2000-04-18 | 2001-11-15 | Stefan Duebel | Verfahren zum Einbringen von Liganden in lebende Zellen |
| WO2001088138A1 (en) * | 2000-05-19 | 2001-11-22 | Scancell Limited | Humanised antibodies to the epidermal growth factor receptor |
| PL358582A1 (en) | 2000-06-29 | 2004-08-09 | Merck Patent Gmbh | Enhancement of antibody-cytokine fusion protein mediated immune responses by combined treatment with immunocytokine uptake enhancing agents |
| US7754676B2 (en) | 2000-09-15 | 2010-07-13 | The United States Of America As Represented By The Department Of Health And Human Services | Defensin-antigen fusion proteins |
| WO2002022687A2 (en) | 2000-09-15 | 2002-03-21 | The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Viral chemokine-tumur antigen fusion proteins |
| GB0029407D0 (en) * | 2000-12-01 | 2001-01-17 | Affitech As | Product |
| RU2003129528A (ru) | 2001-03-07 | 2005-04-10 | Мерк Патент ГмбХ (DE) | Способ экспрессии белков, содержащих в качестве компонента гибридный изотип антитела |
| US6992174B2 (en) | 2001-03-30 | 2006-01-31 | Emd Lexigen Research Center Corp. | Reducing the immunogenicity of fusion proteins |
| MXPA03009924A (es) | 2001-05-03 | 2004-01-29 | Merck Patent Gmbh | Anticuerpo recombinante especifico de tumor y uso del mismo. |
| EP1256354A1 (de) * | 2001-05-11 | 2002-11-13 | Schering Corporation | Verfahren zur Behandlung von Krebs |
| US20020193569A1 (en) * | 2001-06-04 | 2002-12-19 | Idec Pharmaceuticals Corporation | Bispecific fusion protein and method of use for enhancing effector cell killing of target cells |
| US7595378B2 (en) | 2001-06-13 | 2009-09-29 | Genmab A/S | Human monoclonal antibodies to epidermal growth factor receptor (EGFR) |
| BRPI0210405B8 (pt) | 2001-06-13 | 2021-05-25 | Genmab As | anticorpo monoclonal humano, molécula biespecífica, método in vitro para inibir o crescimento de uma célula expressando egfr, para induzir a citólise de uma célula expressando egfr, e para detectar a presença de antígeno egfr ou uma célula expressando egfr em uma amostra, e, vetor de expressão |
| WO2003002609A2 (en) * | 2001-06-28 | 2003-01-09 | Domantis Limited | Dual-specific ligand and its use |
| GB0126378D0 (en) * | 2001-11-02 | 2002-01-02 | Oxford Biomedica Ltd | Antigen |
| DK1454138T3 (da) | 2001-12-04 | 2012-02-13 | Merck Patent Gmbh | Immunocytokiner med moduleret selektivitet |
| JP4212921B2 (ja) | 2002-03-29 | 2009-01-21 | 独立行政法人科学技術振興機構 | 抗体を提示するタンパク質中空ナノ粒子を用いる治療薬剤およびタンパク質中空ナノ粒子 |
| US7696320B2 (en) | 2004-08-24 | 2010-04-13 | Domantis Limited | Ligands that have binding specificity for VEGF and/or EGFR and methods of use therefor |
| AU2003244817B2 (en) * | 2002-06-28 | 2010-08-26 | Domantis Limited | Antigen-binding immunoglobulin single variable domains and dual-specific constructs |
| US9321832B2 (en) * | 2002-06-28 | 2016-04-26 | Domantis Limited | Ligand |
| US20040110929A1 (en) * | 2002-07-12 | 2004-06-10 | Bjorn Soren E. | TF binding compound |
| DK1551876T3 (da) | 2002-10-16 | 2011-06-14 | Purdue Pharma Lp | Antistoffer, der binder til celle-associerede ca 125/0722P og fremgangsmåder til anvendelse deraf |
| US7388079B2 (en) * | 2002-11-27 | 2008-06-17 | The Regents Of The University Of California | Delivery of pharmaceutical agents via the human insulin receptor |
| EP1572748B1 (de) | 2002-12-17 | 2010-06-23 | MERCK PATENT GmbH | Humanisierter antikörper (h14.18) des maus antikörpers 14.18, der gd2 bindet und seine fusion mit il-2 |
| AU2003290330A1 (en) * | 2002-12-27 | 2004-07-22 | Domantis Limited | Dual specific single domain antibodies specific for a ligand and for the receptor of the ligand |
| WO2004074437A2 (en) * | 2003-02-14 | 2004-09-02 | University Of Southern California | Compositions and methods for cancer immunotherapy |
| WO2004080477A1 (en) * | 2003-03-12 | 2004-09-23 | Dana-Farber Cancer Institute, Inc. | Aplidine for multiple myeloma treatment |
| DK1699822T3 (da) | 2003-12-30 | 2008-08-04 | Merck Patent Gmbh | IL-7-fusionsproteiner med antistofdele, fremstilling deraf og anvendelse deraf |
| JP2008504008A (ja) | 2003-12-31 | 2008-02-14 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフトング | 改良された薬物動態を有するＦｃ−エリスロポエチン融合タンパク質 |
| EP1702069A2 (de) | 2004-01-05 | 2006-09-20 | EMD Lexigen Research Center Corp. | Auf onkofötales fibronectin gerichtetes interleukin-12 |
| PL1735348T3 (pl) * | 2004-03-19 | 2012-11-30 | Imclone Llc | Ludzkie przeciwciało przeciwko receptorowi naskórkowego czynnika wzrostu |
| US7670595B2 (en) | 2004-06-28 | 2010-03-02 | Merck Patent Gmbh | Fc-interferon-beta fusion proteins |
| DE602005020837D1 (de) | 2004-12-09 | 2010-06-02 | Merck Patent Gmbh | Il-7-varianten mit reduzierter immunogenität |
| GB2424886A (en) * | 2005-04-04 | 2006-10-11 | Dxs Ltd | Polynucleotide primers against epidermal growth factor receptor and method of detecting gene mutations |
| RU2290948C1 (ru) * | 2005-06-14 | 2007-01-10 | Северо-Осетинская государственная медицинская академия | Способ получения интерлейкина-8 из нейтрофилов крови доноров |
| US8124095B2 (en) * | 2005-10-07 | 2012-02-28 | Armagen Technologies, Inc. | Fusion proteins for delivery of erythropoietin to the CNS |
| US8741260B2 (en) * | 2005-10-07 | 2014-06-03 | Armagen Technologies, Inc. | Fusion proteins for delivery of GDNF to the CNS |
| US8142781B2 (en) * | 2005-10-07 | 2012-03-27 | Armagen Technologies, Inc. | Fusion proteins for blood-brain barrier delivery |
| JP2009519011A (ja) * | 2005-12-01 | 2009-05-14 | ドマンティス リミテッド | インターロイキン１受容体１型に結合する非競合ドメイン抗体フォーマット |
| WO2008022349A2 (en) * | 2006-08-18 | 2008-02-21 | Armagen Technologies, Inc. | Agents for blood-brain barrier delivery |
| CN101173008B (zh) * | 2006-11-01 | 2011-06-22 | 复旦大学 | 一种双功能融合蛋白及其制备方法和应用 |
| WO2008137066A1 (en) * | 2007-05-02 | 2008-11-13 | The Board Of Regents Of The University Of Oklahoma | Use of compacted nucleic acid nanoparticles in non-viral treatments of ocular diseases |
| EA200901301A1 (ru) | 2007-06-06 | 2010-06-30 | Домантис Лимитед | Полипептиды, вариабельные домены антител и антагонисты |
| EP2997976A1 (de) * | 2007-07-27 | 2016-03-23 | Armagen Technologies, Inc. | Verfahren und zusammensetzungen zur erhöhung der alpha-iduronidase-aktivität im zns |
| CN103880965B (zh) | 2007-09-21 | 2018-02-16 | 加利福尼亚大学董事会 | 被导靶的干扰素显示强的细胞凋亡和抗肿瘤活性 |
| US20090226435A1 (en) * | 2008-03-08 | 2009-09-10 | Sanjay Khare | Engineered fusion molecules immunotherapy in cancer and inflammatory diseases |
| US20100098693A1 (en) * | 2008-10-07 | 2010-04-22 | Pardridge William M | Compositions and methods for blood-brain barrier delivery of organophosphatases |
| CN102482347B (zh) | 2009-01-12 | 2017-04-26 | 希托马克斯医疗有限责任公司 | 修饰抗体组合物及其制备和使用方法 |
| JP5873003B2 (ja) | 2009-03-18 | 2016-03-01 | アーメイゲン・テクノロジーズ・インコーポレイテッドＡｒｍａｇｅｎ Ｔｅｃｈｎｏｌｏｇｉｅｓ， Ｉｎｃ． | ＩｇＧデコイ受容体融合タンパク質の血液脳関門送達のための組成物および方法 |
| SG175233A1 (en) | 2009-04-22 | 2011-11-28 | Merck Patent Gmbh | Antibody fusion proteins with modified fcrn binding sites |
| EP2485761B1 (de) | 2009-10-09 | 2019-02-27 | Armagen, Inc. | Verfahren und zusammensetzungen für erhöhte iduronat-2-sulfatase-aktivität im zns |
| UY34317A (es) | 2011-09-12 | 2013-02-28 | Genzyme Corp | Anticuerpo antireceptor de célula T (alfa)/ß |
| KR102096224B1 (ko) | 2011-10-28 | 2020-04-03 | 테바 파마슈티컬즈 오스트레일리아 피티와이 엘티디 | 폴리펩티드 구축물 및 이의 용도 |
| EP2785378B1 (de) | 2011-12-02 | 2020-05-13 | Armagen, Inc. | Verfahren und zusammensetzungen für erhöhte sulfatase-a-aktivität im zns |
| US9790268B2 (en) | 2012-09-12 | 2017-10-17 | Genzyme Corporation | Fc containing polypeptides with altered glycosylation and reduced effector function |
| WO2014089354A1 (en) | 2012-12-07 | 2014-06-12 | The Regents Of The University Of California | Cd138-targeted interferon demonstrates potent apoptotic and anti-tumor activities |
| RU2708314C2 (ru) | 2013-03-11 | 2019-12-05 | Джензим Корпорейшн | Гипергликозилированные связывающие полипептиды |
| EP2992013B1 (de) | 2013-04-29 | 2019-12-04 | Teva Pharmaceuticals Australia Pty Ltd | Anti-cd38-antikörper und fusionen davon mit abgeschwächtem interferon-alpha-2b |
| US11117975B2 (en) | 2013-04-29 | 2021-09-14 | Teva Pharmaceuticals Australia Pty Ltd | Anti-CD38 antibodies and fusions to attenuated interferon alpha-2B |
| US10093745B2 (en) | 2013-05-29 | 2018-10-09 | The Regents Of The University Of California | Anti-CSPG4 fusions with interferon for the treatment of malignancy |
| EP3129067B1 (de) | 2014-03-19 | 2023-01-04 | Genzyme Corporation | Ortsspezifisches glycoengineering von targeting-teilen |
| UA119352C2 (uk) | 2014-05-01 | 2019-06-10 | Тева Фармасьютикалз Острейліа Пті Лтд | Комбінація леналідоміду або помалідоміду і конструкції анти-cd38 антитіло-атенуйований інтерферон альфа-2b та спосіб лікування суб'єкта, який має cd38-експресуючу пухлину |
| CN108025083B (zh) | 2014-10-09 | 2021-09-03 | 建新公司 | 糖工程化的抗体药物缀合物 |
| UA125637C2 (uk) | 2014-10-29 | 2022-05-11 | Тева Фармасьютікалз Острейліа Пті Лтд | ЗЛИТИЙ ПОЛІПЕПТИД ІНТЕРФЕРОНУ <font face="Symbol">a2</font>b |
| US10538589B2 (en) | 2015-01-14 | 2020-01-21 | Armagen Inc. | Methods and compositions for increasing N-acetylglucosaminidase (NAGLU) activity in the CNS using a fusion antibody comprising an anti-human insulin receptor antibody and NAGLU |
| CA3001154C (en) * | 2015-10-07 | 2023-10-17 | Sangui Bio Pty. Ltd | Blood preparation and profiling |
| US11618784B2 (en) | 2016-07-19 | 2023-04-04 | Teva Pharmaceuticals Australia Pty Ltd. | Anti-CD47 combination therapy |
| EP3688022A4 (de) * | 2017-09-29 | 2021-09-22 | NantCell, Inc. | Antigenproteine und verfahren dafür |
| EP3898626A1 (de) | 2018-12-19 | 2021-10-27 | Array Biopharma, Inc. | Substituierte pyrazolo[1,5-a]pyridin-verbindungen als inhibitoren von fgfr-tyrosinkinasen |
| WO2020131674A1 (en) | 2018-12-19 | 2020-06-25 | Array Biopharma Inc. | 7-((3,5-dimethoxyphenyl)amino)quinoxaline derivatives as fgfr inhibitors for treating cancer |
| CA3135032A1 (en) | 2019-04-03 | 2020-10-08 | Genzyme Corporation | Anti-alpha beta tcr binding polypeptides with reduced fragmentation |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8605316D0 (en) * | 1986-03-04 | 1986-04-09 | Royal Free Hosp School Med | Immunosuppression |
| IL85035A0 (en) * | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
| US5470571A (en) * | 1988-01-27 | 1995-11-28 | The Wistar Institute | Method of treating human EGF receptor-expressing gliomas using radiolabeled EGF receptor-specific MAB 425 |
| IE62463B1 (en) * | 1988-07-07 | 1995-02-08 | Res Dev Foundation | Immunoconjugates for cancer diagnosis and therapy |
| ZA902949B (en) * | 1989-05-05 | 1992-02-26 | Res Dev Foundation | A novel antibody delivery system for biological response modifiers |
| US5112946A (en) * | 1989-07-06 | 1992-05-12 | Repligen Corporation | Modified pf4 compositions and methods of use |
| US5314995A (en) * | 1990-01-22 | 1994-05-24 | Oncogen | Therapeutic interleukin-2-antibody based fusion proteins |
| ATE158615T1 (de) * | 1990-03-20 | 1997-10-15 | Univ Columbia | Chimäre antikörper mit rezeptor-bindenden liganden anstelle ihrer konstanten region |
| IE62496B1 (en) * | 1990-04-19 | 1995-02-08 | Res Dev Foundation | Antibody conjugates for treatment of neoplastic disease |
| ATE218889T1 (de) * | 1990-11-09 | 2002-06-15 | Stephen D Gillies | Cytokine immunokonjugate |
| WO1992015683A1 (en) * | 1991-03-06 | 1992-09-17 | MERCK Patent Gesellschaft mit beschränkter Haftung | Humanized and chimeric monoclonal antibodies |
| EP0603194A4 (de) * | 1991-07-05 | 1994-12-07 | Seragen Inc | Zum rezeptor des epidermalen wachstumsfaktors zielgesteuerte moleküle zur behandlung entzündlicher arthritis. |
| DK0586002T3 (da) * | 1992-08-18 | 2000-06-19 | Centro Inmunologia Molecular | Monoklonale antistoffer, som genkender epidermisvækstfaktor-receptoren, celler og fremgangsmåder heraf og præparater indeho |
-
1995
- 1995-09-06 DK DK95113956T patent/DK0706799T3/da active
- 1995-09-06 AT AT95113956T patent/ATE208633T1/de not_active IP Right Cessation
- 1995-09-06 PT PT95113956T patent/PT706799E/pt unknown
- 1995-09-06 ES ES95113956T patent/ES2167391T3/es not_active Expired - Lifetime
- 1995-09-06 EP EP95113956A patent/EP0706799B1/de not_active Expired - Lifetime
- 1995-09-06 DE DE69523857T patent/DE69523857T2/de not_active Expired - Fee Related
- 1995-09-08 AU AU30533/95A patent/AU702184B2/en not_active Ceased
- 1995-09-11 JP JP23283295A patent/JP3865802B2/ja not_active Expired - Fee Related
- 1995-09-13 SK SK1145-95A patent/SK282263B6/sk unknown
- 1995-09-14 UA UA95094164A patent/UA40611C2/uk unknown
- 1995-09-14 CA CA002158322A patent/CA2158322C/en not_active Expired - Fee Related
- 1995-09-14 CZ CZ19952375A patent/CZ289641B6/cs not_active IP Right Cessation
- 1995-09-14 CN CN95116279A patent/CN1123185A/zh active Pending
- 1995-09-15 PL PL95310493A patent/PL182636B1/pl not_active IP Right Cessation
- 1995-09-15 NO NO19953650A patent/NO315976B1/no not_active IP Right Cessation
- 1995-09-15 HU HU9502711A patent/HU221989B1/hu not_active IP Right Cessation
- 1995-09-15 KR KR1019950030385A patent/KR100386171B1/ko not_active Expired - Fee Related
- 1995-09-15 US US08/528,523 patent/US5824782A/en not_active Expired - Fee Related
- 1995-09-15 ZA ZA957808A patent/ZA957808B/xx unknown
- 1995-09-15 RU RU95115976/14A patent/RU2157701C2/ru not_active IP Right Cessation
-
2005
- 2005-11-17 JP JP2005332965A patent/JP2006117684A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CN1123185A (zh) | 1996-05-29 |
| EP0706799A2 (de) | 1996-04-17 |
| PL310493A1 (en) | 1996-03-18 |
| JP2006117684A (ja) | 2006-05-11 |
| ES2167391T3 (es) | 2002-05-16 |
| AU702184B2 (en) | 1999-02-18 |
| RU2157701C2 (ru) | 2000-10-20 |
| JPH0899901A (ja) | 1996-04-16 |
| NO315976B1 (no) | 2003-11-24 |
| HUT75836A (en) | 1997-05-28 |
| NO953650L (no) | 1996-03-18 |
| CZ237595A3 (en) | 1996-04-17 |
| HU9502711D0 (en) | 1995-11-28 |
| DE69523857D1 (de) | 2001-12-20 |
| HU221989B1 (hu) | 2003-03-28 |
| US5824782A (en) | 1998-10-20 |
| DE69523857T2 (de) | 2002-06-13 |
| UA40611C2 (uk) | 2001-08-15 |
| CA2158322A1 (en) | 1996-03-17 |
| NO953650D0 (no) | 1995-09-15 |
| PT706799E (pt) | 2002-05-31 |
| PL182636B1 (pl) | 2002-02-28 |
| AU3053395A (en) | 1996-03-28 |
| KR960010023A (ko) | 1996-04-20 |
| SK282263B6 (sk) | 2001-12-03 |
| JP3865802B2 (ja) | 2007-01-10 |
| CA2158322C (en) | 2009-06-16 |
| EP0706799A3 (de) | 1996-12-04 |
| SK114595A3 (en) | 1997-03-05 |
| EP0706799B1 (de) | 2001-11-14 |
| KR100386171B1 (ko) | 2003-08-21 |
| DK0706799T3 (da) | 2002-02-25 |
| ZA957808B (en) | 1996-05-07 |
| CZ289641B6 (cs) | 2002-03-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE69523857D1 (de) | Immunokonjugate | |
| DE69729283D1 (de) | GLYKOSYLIERTE IgG ANTIKÖRPER | |
| FI963101A7 (fi) | Anti-TNF-vasta-aineiden käyttö lääkkeenä sellaisten sairauksien hoitoo n, joissa seerumin interleukiini-6-taso on kohonnut | |
| DE69520088D1 (de) | Interferon-gamma-induzierendes Polypeptid monoklonal Antikörper, und Zusammensetzung für Interferon-gamma gebunden Krankheiten | |
| LU93274I2 (fr) | Elotuzumab | |
| ATE178907T1 (de) | Rezeptorbindende region des diphtherietoxius | |
| ATE443139T1 (de) | Menschliche toll-ähliche rezeptorproteine, zugehörige reagenzien und verfahren | |
| EP0610201A4 (de) | Für menschlichen tumornekrose-faktor spezifische monoklonale und chimäre antikörper. | |
| DK101890A (da) | Monoklonale antistoffer mod human interleukin-4 og hybridomaer, der producerer saadanne | |
| NO940219L (no) | Rekombinante antistoffer for human terapi | |
| FI864037A7 (fi) | Monoklonaaliset vasta-aineet ihmisen rintasyöpää vastaan. | |
| DE69519454D1 (de) | Protein, das Interferon-Gamma Herstellung induziert und monoklonaler Antikörper dagegen | |
| DE3783277D1 (de) | Monoklonaler antikoerper gegen humanes lungenkarzinom. | |
| DE68925226D1 (de) | Monoklonale Antikörper | |
| DE69033631D1 (de) | Therapeutische verwendungen der hypervariablen region des monoklonalen antikörpers m195 und konstrukte davon | |
| PT954333E (pt) | Receptores soluveis de linfotoxina-beta, anticorpos de receptores de anti-linfotoxina e anticorpos de ligandos de anti-linfotoxina como agentes terapeuticos para o tratamento de doencas imunologicas | |
| DE68920624D1 (de) | Menschlicher monoklonaler Antikörper, Hybridoma, das ihn herstellt, und pharmazeutisches Mittel. | |
| DK402485A (da) | Tumorterapeutiskum og fremgangsmaade til dets fremstilling | |
| DE3888604D1 (de) | Monoklonale Antikörper gegen Antithrombinbindende Substanz und seine Verwendungen. | |
| DK270386A (da) | Monoklonalt antistof til humant protein c, dets fremstilling og anvendelse | |
| ATE407944T1 (de) | Mit trp-proteinen verwandtes protein mtr1 und dieses codierende dna-sequenz | |
| ATE364180T1 (de) | Screeningverfahren mit bnpi und dnpi | |
| EP1297832A3 (de) | Zusammentsetzung und Verfahren zur Behandlung von Psoriasis | |
| EP0446797A3 (en) | Synthetic peptides containing factor viia sequences and their use | |
| DE3882066D1 (de) | Monoclonaler antikoerper gegen menschliches lungenadenokarzinom. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| UEP | Publication of translation of european patent specification | ||
| REN | Ceased due to non-payment of the annual fee |